Edition:
India

Aurinia Pharmaceuticals Inc (AUP.TO)

AUP.TO on Toronto Stock Exchange

18.91CAD
1:30am IST
Change (% chg)

$0.02 (+0.11%)
Prev Close
$18.89
Open
$19.24
Day's High
$19.27
Day's Low
$18.59
Volume
161,848
Avg. Vol
200,431
52-wk High
$28.59
52-wk Low
$4.70

Select another date:

Mon, Jun 22 2020

BRIEF-Aurinia Completes Patient Enrollment Into Audrey Phase 2/3 Clinical Trial Of Voclosporin Ophthalmic Solution

* AURINIA COMPLETES PATIENT ENROLLMENT INTO THE AUDREY PHASE 2/3 CLINICAL TRIAL OF VOCLOSPORIN OPHTHALMIC SOLUTION FOR THE TREATMENT OF DRY EYE SYNDROME

BRIEF-Aurinia Presents Additional Aurora Pivotal Trial Safety Data At The Era-Edta Virtual Congress 2020

* AURINIA PRESENTS ADDITIONAL AURORA PIVOTAL TRIAL SAFETY DATA AT THE ERA-EDTA VIRTUAL CONGRESS 2020 Source text for Eikon: Further company coverage:

BRIEF-Aurinia Presents Aurora Pivotal Trial Subgroup Analysis At Eular

* AURINIA PRESENTS AURORA PIVOTAL TRIAL SUBGROUP ANALYSIS AT THE EULAR 2020 E-CONGRESS Source text for Eikon: Further company coverage:

BRIEF-Aurinia Pharma Files For Mixed Shelf Of Up To Us $500 Mln

* AURINIA PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UP TO US $500 MILLION – SEC FILING Source text: (https://bit.ly/3euVkNi) Further company coverage:

BRIEF-Aurinia Completes Submission Of New Drug Application To U.S. FDA For Voclosporin For Treatment Of Lupus Nephritis

* AURINIA COMPLETES SUBMISSION OF NEW DRUG APPLICATION TO U.S. FOOD & DRUG ADMINISTRATION FOR VOCLOSPORIN FOR TREATMENT OF LUPUS NEPHRITIS Source text for Eikon: Further company coverage:

BRIEF-Aurinia Pharmaceuticals Q1 Loss Per Share $0.15

* AURINIA REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND RECENT OPERATIONAL HIGHLIGHTS

BRIEF-Aurinia Appoints Joe Miller As Chief Financial Officer

* AURINIA PHARMACEUTICALS INC - DENNIS BOURGEAULT TO RETIRE AFTER MORE THAN 20 YEARS WITH COMPANY

BRIEF-Aurinia Announces Aurora Phase 3 Clinical Data For Voclosporin

* AURINIA ANNOUNCES AURORA PHASE 3 CLINICAL DATA FOR VOCLOSPORIN IN LUPUS NEPHRITIS TO BE PRESENTED AT NATIONAL KIDNEY FOUNDATION 2020 SPRING CLINICAL MEETINGS Source text for Eikon: Further company coverage:

BRIEF-Aurinia Pharmaceuticals Establishes U.S. Commercial Operations Center In Rockville, Maryland

* AURINIA PHARMACEUTICALS ESTABLISHES U.S. COMMERCIAL OPERATIONS CENTER IN ROCKVILLE, MARYLAND Source text for Eikon: Further company coverage:

BRIEF-Aurinia Pharmaceuticals Initiates Rolling Submission Of A New Drug Application To The U.S. FDA For Voclosporin

* AURINIA PHARMACEUTICALS INITIATES ROLLING SUBMISSION OF A NEW DRUG APPLICATION TO THE U.S. FOOD AND DRUG ADMINISTRATION FOR VOCLOSPORIN IN THE TREATMENT OF LUPUS NEPHRITIS

Select another date: